Please ensure Javascript is enabled for purposes of website accessibility

How Dynavax Demolished Expectations With Its Q1 Results

By Keith Speights - May 7, 2021 at 6:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's hepatitis B vaccine wasn't its key growth driver.

Who wouldn't love a stock that has more than doubled in a little over five months? That's exactly what Dynavax Technologies (DVAX -5.76%) has done, thanks partially to good news in April for its COVID-19 vaccine partner Valneva.

Dynavax announced its first-quarter results after the market closed on Thursday. Its momentum seems likely to continue, with the biotech stock rising nearly 6% in after-hours trading. Here are the highlights from Dynavax's Q1 update.

Lab worker holding a micro pipette.

Image source: Getty Images.

By the numbers

Dynavax reported revenue in the first quarter of $83.3 million. This was more than seven times greater than the company's revenue of $10.9 million in the prior-year period. It also trounced the Wall Street consensus estimate of $59.1 million.

The company announced net income in the first quarter of $891,000, or $0.01 per share, based on generally accepted accounting principles (GAAP). That was a lot better than the GAAP net loss of $12.6 million, or $0.25 per share, posted in the prior-year period. And it beat the average analyst estimate of a net loss of $0.02 per share.

Dynavax ended the first quarter with cash, cash equivalents, and short-term investments of $232.7 million. This reflected a solid increase from the $165 million on hand as of Dec. 31, 2020.

Behind the numbers

The big story for Dynavax in Q1 was the collaboration for its vaccine adjuvant CpG 1018. Dynavax recorded $74.6 million in net product revenue for the adjuvant. It didn't make a penny from CpG 1018 in the first quarter of 2020.

There was good news and bad news in the first quarter for the company's hepatitis B vaccine Heplisav-B. The bad news was that sales fell 21% year over year to $8.3 million due to reduced utilization stemming from the COVID-19 pandemic. The good news was that the market share for Heplisav-B in targeted accounts jumped to 27% from 21% in the prior-year period. 

As you might expect with increased manufacturing costs for Cpg 1018, Dynavax's spending rose quite a bit in the  first quarter of 2021, compared to the same period in 2020. However, total operating expenses didn't grow nearly as fast as revenue did, leading to the company's impressive bottom-line improvement.

Looking ahead

Dynavax CEO Ryan Spencer said that the company "believe[s] 2021 will be a transformational year." That could very well be the case.

The biotech's collaboration partners should report clinical results throughout 2021. CpG 1018 could prove to be a growth driver not just this year but well into the future. It's being used as an adjuvant not only for COVID-19 vaccines, but also for pertussis and flu vaccines.

Heplisav-B appears to be on track to become the standard of care for hepatitis B vaccination in the U.S. Dynavax also plans to launch the vaccine in Europe in the fourth quarter. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$16.43 (-5.76%) $-1.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.